SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

University of Michigan Rogel Cancer Center60 enrolled

Overview

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Castration-Resistant Prostate Carcinoma

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \* 177Lu-617 PSMA treatment scheduled for mCRPC * Clinically stable as determined by the nuclear medicine clinicians * Male * ≥ 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Locations (1)

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

RECRUITING

Outcomes

Primary Outcomes

Response and toxicity following 177Lu-RLT

Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT

Time frame: Up to 4 years

Secondary Outcomes

Build and test models

Build and test models for predicting therapy delivered absorbed dose from pre-therapy PET imaging/non-imaging biomarkers.

Time frame: Up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.